Pricing Log in Create free account
Friday 6 November 2026 Export PAHC’s income statement to Excel — free account

Phibro Animal Health Corporation

PAHC Healthcare Drug Manufacturers Specialty & Generic

Phibro Animal Health Corporation’s revenue for fiscal 2026 (year ended June 2026) was $1.5 billion, up 17.1% from fiscal 2025.

Revenue
+6.29%
EPS
+12.3%
Free cash flow
+262.1%
Total debt
−1.09%

Quarter to September 2026, against a year earlier

35.54 3.89 −9.87%
Market cap
$1.4B
P/E
14.0×
Fwd P/E
12.6×
Dividend yield
1.35%
F-score
6/9
Altman Z
2.95
Beneish M
−2.39
Dividend safety
47/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.32
Sold, $m 23.15
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — 1 — — — — — —
Sell 3 6 6 4 3 1 — — — — — —
Insider Ownership 48.46%

Capital & Financial Ratios $m

Size
Market Cap 1,440.00
Revenue ttm 1,540.97
Net income ttm 102.71
Free cash flow ttm 21.67
Net debt Q 651.75
Valuation
P/E 13.99
Forward P/E 12.60
Price / sales 0.94
Forward P/S Powerpack
Price / FCF 66.57
Price / book 3.45
Financial health
Current ratio Q 3.20 (at or above 1.5: strong)
Debt / equity Q 1.76
Interest coverage Q 4.40
Growth
Revenue growth Q +6.29% (above 0%: growing)
Operating income growth Q −3.16% (below 0%: shrinking)
EPS, this year +8.60%
EPS, next year A +10.07%
Revenue, next year A +3.88%
EPS, past 5 yrs +12.64%
EPS, next 5 yrs A +8.47%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.4×, against a ten-year median of 1.5×; over the ten years it ranged from 0.8× in 2023 to 2.6× in 2018.
P/E against its own 10 years 13.93%
10-year low 10-year high
P/S against its own 10 years 36.19%
10-year low 10-year high
P/B against its own 10 years 26.81%
10-year low 10-year high
EV/Sales against its own 10 years 36.12%
10-year low 10-year high
EV/FCF against its own 10 years 80.07%
10-year low 10-year high

Dividends

Yield
1.35%
Annual rate
0.48
Payout ratio
19.1%
Growth, 2017–25
+2.31%/yr
  1. 0.40 ’17
  2. 0.42 ’18 +5
  3. 0.48 ’19 +14
  4. 0.48 ’20 +0
  5. 0.48 ’21 +0
  6. 0.48 ’22 +0
  7. 0.48 ’23 +0
  8. 0.48 ’24 +0
  9. 0.48 ’25 +0
  10. 0.48 ’26e +0
paid forecast change on the year, % Powerpack

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 115 77 82 83
Receivables 169 228 239 222
Inventory 266 444 535 567
Other 51 61 80 73
601 811 936 945
2024 2025 2026 Q'26
Payables 86 138 127 136
ST’ Debt 30 16 25 25
Other — — — —
204 293 316 296

Compound Annual Growth %

10y 5y 3y
Sales 7.28% 12.74% 15.79%
Cash Flow 6.36% 7.38% 73.03%
Earnings 1.89% 12.89% 45.15%
Book Value 15.60% 10.08% 10.91%

Earnings Trends EPS, adjusted, against the consensus

Q1 FY27 Estimate 0.79 Actual 0.79

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY26 0.69 0.87 Beat by 0.18
Q3 FY26 0.72 0.76 Beat by 0.04
Q4 FY26 0.72 0.85 Beat by 0.13
Q1 FY27 0.79 0.79 Met by 0.00
Q2 FY27 0.94 — Reports 3 February 2027

EPS $

Sep Dec Mar Jun Year
’26 0.72 — — — —
’26 0.65 0.67 0.59 0.53 2.43
’25 0.17 0.08 0.51 0.42 1.19
’24 (0.20) 0.03 0.21 0.02 0.06
’23 0.10 0.18 0.25 0.28 0.81
’22 0.16 0.43 0.44 0.18 1.21
’21 0.30 0.32 0.30 0.42 1.34
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 387 — — — —
’26 364 374 384 397 1,518
’25 260 309 348 379 1,296
’24 231 250 263 273 1,018
’23 233 245 246 255 978
’22 215 233 240 255 942
’21 195 206 212 220 833
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 26 — — — —
’26 9 19 16 24 69
’25 13 3 43 21 80
’24 16 32 11 28 88
’23 (11) (2) 6 20 13
’22 4 20 6 2 32
’21 2 27 17 3 48
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 7 — — — —
’26 (5) 8 1 5 10
’25 3 (5) 35 8 42
’24 9 21 2 15 46
’23 (34) (12) (2) 9 (38)
’22 (4) 12 (4) (10) (5)
’21 (6) 20 9 (4) 19
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Sep ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 764 820 828 800 833 942 978 1,018 1,296 1,518 1,541 +7.9% 1,577 1,632 1,679 +3.4%
Gross margin, % 32.48 32.55 31.96 32.10 32.56 30.29 30.50 30.77 30.85 33.76 33.83 +1.3 pt
EBT 81 88 72 56 66 72 54 11 68 137 140 +6.1%
EBT margin, % 10.54 10.74 8.64 6.94 7.98 7.68 5.53 1.07 5.25 9.05 9.08 (1.5) pt
Net income 65 65 55 34 54 49 33 2 48 100 103 +4.9%
Per share, $
Per share, $ Revenue 19.34 20.41 20.49 19.78 20.59 23.26 24.14 25.13 31.99 37.44 37.97 +7.6%
Earnings 1.63 1.61 1.35 0.83 1.34 1.21 0.81 0.06 1.19 2.46 2.54 +4.7%
Cash flow 2.49 1.74 1.17 1.47 1.19 0.78 0.33 2.16 1.98 1.70 2.11 (4.1%)
Capex (0.53) (0.46) (0.74) (0.84) (0.72) (0.91) (1.28) (1.02) (0.95) (1.46) (1.58) +11.9%
Free cash flow 1.96 1.28 0.43 0.63 0.47 (0.13) (0.95) 1.14 1.03 0.24 0.53 (20.7%)
Book value 3.82 4.60 5.35 4.65 5.89 6.48 6.97 6.34 7.05 9.51 10.29 +10.6%
Shares, m 40 40 40 40 40 41 41 41 41 41 41 +0.3%
Valuation, ×
Valuation, × P/E 22.59 29.10 23.25 32.04 21.55 15.81 16.91 284.00 21.46 12.76 13.99 47.9
P/S 1.92 2.30 1.54 1.33 1.40 0.82 0.57 0.68 0.80 0.84 0.94 1.2
P/B 9.69 10.18 5.92 5.65 4.90 2.95 1.96 2.69 3.62 3.30 3.45 5.1
EV/Sales 2.25 2.58 1.84 1.70 1.76 1.18 0.97 1.05 1.29 1.27 1.36 1.6
EV/FCF 22.21 41.11 88.11 53.69 77.31 (206.95) (24.65) 22.95 40.08 195.01 96.64 30.9
Cash, $m
Cash, $m Operating cash flow 98 70 47 59 48 32 13 88 80 69 86 (3.9%)
Capex (21) (19) (30) (34) (29) (37) (52) (41) (38) (59) (64) +12.3%
Free cash flow 78 51 17 25 19 (5) (38) 46 42 10 22 (20.5%)
Balance, $m
Balance, $m Working capital 248 272 312 295 335 375 410 397 517 619 649 +10.7%
Net debt 257 233 245 296 299 342 394 373 642 651 652 +10.9%
Shareholders’ equity 151 185 216 188 239 262 283 257 286 385 418 +11.0%
Returns, %
Returns, % ROA 10.50 10.02 7.83 4.44 6.69 5.55 3.43 0.25 4.12 6.97 7.08 (3.5) pt
ROIC 14.99 14.79 11.29 8.94 8.71 8.17 6.64 5.29 7.45 11.72 11.27 (3.3) pt
ROE 53.48 38.61 27.29 16.60 25.49 19.63 11.97 0.90 17.80 29.72 28.17 (23.8) pt
People
People Employees 1,400 1,500 1,600 2,500 1,725 1,860 1,920 1,940 2,475 2,605 — +7.1%
Revenue/emp, $m 0.55 0.55 0.52 0.32 0.48 0.51 0.51 0.52 0.52 0.58 — +0.7%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2026 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

Phibro Animal Health Corporation vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
XERS Xeris Biopharma Holdings, Inc. $2.4B — (loss-making) — (loss-making) +44.16% (above 0%: growing) +1,478.95% (above 0%: growing) +93.18% (above 0%: growing) 88.41% 15.78% Compare
BCRX BioCryst Pharmaceuticals, Inc. $2.0B — (loss-making) — (loss-making) +13.11% (above 0%: growing) +150.00% (above 0%: growing) −18.69% (below 0%: shrinking) 99.13% 29.58% Compare
ALVO Alvotech $1.8B — (loss-making) 111× +2,310.95% (above 0%: growing) −99.51% (below 0%: shrinking) −496.58% (below 0%: shrinking) 56.47% 9.14% Compare
ANIP ANI Pharmaceuticals, Inc. $1.6B 13.3× 14.3× +27.64% (above 0%: growing) +29.41% (above 0%: growing) +85.49% (above 0%: growing) 61.64% 18.01% Compare
PCRX Pacira BioSciences, Inc. $1.5B 38.4× 56.6× −1.59% (below 0%: shrinking) +500.00% (above 0%: growing) −18.47% (below 0%: shrinking) 0.00% 12.61% Compare
PAHC Phibro Animal Health Corporation $1.4B 14.0× 12.6× +6.29% (above 0%: growing) +12.31% (above 0%: growing) +262.08% (above 0%: growing) 33.23% 12.83%
CRON Cronos Group Inc. $1.4B 21.9× 19.5× +74.61% (above 0%: growing) −42.86% (below 0%: shrinking) +179.64% (above 0%: growing) 50.88% 14.23% Compare
ETON Eton Pharmaceuticals, Inc. $1.4B 26.8× 48.0× +157.91% (above 0%: growing) n/m +172.55% (above 0%: growing) 76.48% 39.73% Compare
AMPH Amphastar Pharmaceuticals, Inc. $1.2B 12.3× 12.8× +8.22% (above 0%: growing) +134.21% (above 0%: growing) −29.38% (below 0%: shrinking) 47.99% 24.46% Compare
Median of peers $1.5B 21.9× 33.8× +35.90% +134.21% +33.51% 59.05% 16.90%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 18 September 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2026 5.23m 5.20m 123.00
2025 5.28m 5.12m 111.00
2024 4.75m 3.96m 72.00
2023 2.94m 2.90m 56.00
2022 3.61m 3.56m 76.00
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Phibro Animal Health Corporation (PAHC) Latest News

5 Nov

Impact 3 · · MarketBeat transcript

4 Nov

Impact 3 · · StockStory
Impact 3 · · Business Wire

28 Oct

Impact 4 · · Zacks
Impact 3 · · Business Wire

27 Oct

Impact 3 · · Zacks

24 Oct

Impact 4 · · Simply Wall St.

23 Oct

Impact 4 · · Zacks
Impact 3 ·

22 Oct

Impact 3 · · Zacks

21 Oct

Impact 3 · · Zacks

16 Oct

Impact 3 · · Zacks

9 Oct

Impact 4 · · Simply Wall St.

8 Oct

Impact 4 · · Zacks

28 Sep

Impact 3 ·

25 Sep

Impact 3 · · Zacks

24 Sep

Impact 3 · · StockStory

4 Sep

Impact 3 ·

1 Sep

Impact 4 ·

31 Aug

Impact 3 · · The Motley Fool transcript

28 Aug

Impact 3 ·

27 Aug

Impact 4 · transcript
Impact 3 · · MarketBeat
Impact 3 · · Moby transcript

26 Aug

Impact 4 ·
Impact 4 ·
Impact 3 ·

25 Aug

Impact 3 ·

21 Aug

Impact 3 ·

20 Aug

Impact 3 ·
stockrow.com/PAHC · Data as of Nov 4, 2026 · For information only; not investment advice. · © 2026 stockrow.com